Literature DB >> 24467768

Co-expression of HER3 and MUC1 is associated with a favourable prognosis in patients with bladder cancer.

Trine O Nielsen1, Michael Borre, Ebba Nexo, Boe S Sorensen.   

Abstract

OBJECTIVES: To investigate the functional impact of the interaction of MUC1 with the epidermal growth factor receptors HER3 and HER4 in patients with bladder cancer. PATIENTS AND METHODS: Using reverse transcription quantitative polymerase chain reaction, we examined MUC1 expression in 82 bladder cancer biopsies previously examined for the expression of HER3.
RESULTS: Patients expressing high MUC1 had a favourable survival when the expression of HER3 was also high compared with when the expression of HER3 was low (P = 0.004). When MUC1 expression was low, HER3 co-expression did not influence the prognostic value of MUC1 (P = 0.488). MUC1 expression had no correlation with survival, tumour stage or grade, or to the prognostic value of HER4.
CONCLUSIONS: A high MUC1 expression was associated with a favourable prognosis in patients with bladder cancer when the expression of HER3 was also high. This suggests an involvement of HER3 in MUC1 function in bladder cancer.
© 2014 The Authors. BJU International © 2014 BJU International.

Entities:  

Keywords:  EGF system; HER3; HER4; MUC1; bladder cancer

Mesh:

Substances:

Year:  2015        PMID: 24467768     DOI: 10.1111/bju.12658

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  6 in total

1.  Soluble HER3 predicts survival in bladder cancer patients.

Authors:  Ashfaque A Memon; Stephen C Gilliver; Michael Borre; Jan Sundquist; Kristina Sundquist; Ebba Nexo; Boe S Sorensen
Journal:  Oncol Lett       Date:  2017-11-22       Impact factor: 2.967

Review 2.  Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?

Authors:  Rita Azevedo; Andreia Peixoto; Cristiana Gaiteiro; Elisabete Fernandes; Manuel Neves; Luís Lima; Lúcio Lara Santos; José Alexandre Ferreira
Journal:  Oncotarget       Date:  2017-07-21

3.  Altered Proteome of Extracellular Vesicles Derived from Bladder Cancer Patients Urine.

Authors:  Jingyun Lee; Kimberly Q McKinney; Antonis J Pavlopoulos; Meng Niu; Jung Won Kang; Jae Won Oh; Kwang Pyo Kim; Sunil Hwang
Journal:  Mol Cells       Date:  2018-03-09       Impact factor: 5.034

Review 4.  Extracellular Vesicles in Bladder Cancer: Biomarkers and Beyond.

Authors:  Yu-Ru Liu; Carlos J Ortiz-Bonilla; Yi-Fen Lee
Journal:  Int J Mol Sci       Date:  2018-09-18       Impact factor: 5.923

5.  HER3 signaling and targeted therapy in cancer.

Authors:  Rosalin Mishra; Hima Patel; Samar Alanazi; Long Yuan; Joan T Garrett
Journal:  Oncol Rev       Date:  2018-05-16

6.  Crystal structures of HER3 extracellular domain 4 in complex with the designed ankyrin-repeat protein D5.

Authors:  Filip Radom; Clemens Vonrhein; Peer R E Mittl; Andreas Plückthun
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2021-06-29       Impact factor: 1.056

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.